See more : Powertip Technology Corporation (6167.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Olema Pharmaceuticals, Inc. (OLMA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Olema Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Dongfang Electric Corporation Limited (1072.HK) Income Statement Analysis – Financial Results
- CG Oncology, Inc. Common stock (CGON) Income Statement Analysis – Financial Results
- e-LogiT co.,ltd. (9327.T) Income Statement Analysis – Financial Results
- TECON BIOLOGY Co.LTD (002100.SZ) Income Statement Analysis – Financial Results
- Medibank Private Limited (MDBPF) Income Statement Analysis – Financial Results
Olema Pharmaceuticals, Inc. (OLMA)
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 377.00K | 1.66M | 1.66M | 11.00K | 9.03K | 8.24K |
| Gross Profit | -377.00K | -1.66M | -1.66M | -11.00K | -9.03K | -8.24K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 86.14M | 82.27M | 51.10M | 13.70M | 3.92M | 1.69M |
| General & Administrative | 18.82M | 24.71M | 20.39M | 7.82M | 403.00K | 386.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 18.82M | 24.71M | 20.39M | 7.82M | 403.00K | 386.00K |
| Other Expenses | 0.00 | -27.00K | -47.00K | 0.00 | 0.00 | -31.00K |
| Operating Expenses | 104.96M | 106.99M | 71.49M | 21.53M | 4.32M | 2.08M |
| Cost & Expenses | 104.96M | 106.99M | 71.49M | 21.53M | 4.32M | 2.08M |
| Interest Income | 8.32M | 2.23M | 442.00K | 60.00K | 7.00K | 4.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 653.00K | 0.00 | 28.00K |
| Depreciation & Amortization | 377.00K | 1.66M | 1.66M | 11.00K | 9.03K | 8.24K |
| EBITDA | -104.58M | -103.13M | -69.43M | -21.52M | -4.31M | -2.16M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -104.96M | -106.99M | -71.49M | -21.53M | -4.32M | -2.08M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.31M | 2.20M | 395.00K | -593.00K | 7.00K | -118.00K |
| Income Before Tax | -96.66M | -104.79M | -71.10M | -22.12M | -4.32M | -2.20M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -2.20M | -210.00K | 642.00K | -155.86K | -90.00K |
| Net Income | -96.66M | -102.59M | -70.89M | -22.76M | -4.32M | -2.20M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.14 | -2.56 | -1.79 | -0.58 | -0.11 | -0.16 |
| EPS Diluted | -2.14 | -2.56 | -1.79 | -0.58 | -0.11 | -0.16 |
| Weighted Avg Shares Out | 45.25M | 40.00M | 39.52M | 39.31M | 40.17M | 14.10M |
| Weighted Avg Shares Out (Dil) | 45.25M | 40.00M | 39.52M | 39.31M | 40.17M | 14.10M |
Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant
SAN FRANCISCO, Oct. 22, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, or the “Company”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced results from...
Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors
Mr. Garland brings significant industry expertise with a long track record of successful launches Mr. Garland brings significant industry expertise with a long track record of successful launches
Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress
Oral presentation by Dr. Nancy U. Lin from Dana-Farber Cancer Institute at 8:55 a.m. CEST/2:55 a.m. ET on October 22, 2023 Olema will host an investor conference call at 8:00 a.m. ET on October 23, 2023
Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity
Preclinical data to be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Preclinical data to be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Wall Street Analysts Believe Olema Pharmaceuticals, Inc. (OLMA) Could Rally 76.47%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 76.5% in Olema Pharmaceuticals, Inc. (OLMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate...
Here's Why Momentum in Olema Pharmaceuticals, Inc. (OLMA) Should Keep going
Olema Pharmaceuticals, Inc. (OLMA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that the Company granted...
7 ‘Strong Buy' Biotech Stocks to Rejuvenate Your Portfolio
While the health innovation space presents wild risks, you could potentially swing the odds in your favor with strong buy biotech stocks. Specifically, these ideas represent publicly traded biotechnology firms that enjoy the highest possible consensus rating among Wall Street...
Does Olema Pharmaceuticals, Inc. (OLMA) Have the Potential to Rally 80.29% as Wall Street Analysts Expect?
The mean of analysts' price targets for Olema Pharmaceuticals, Inc. (OLMA) points to an 80.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an...
Olema Oncology Announces New Preclinical KAT6 Inhibitor Data to be Presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
SAN FRANCISCO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced a poster presentation on...
Source: https://incomestatements.info
Category: Stock Reports